FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 74 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR 2022 ASCO Annual Meeting Research Round Up: New Research in Lung... September 15, 2022 Philanthropist Simon Collins: “I realised I could make a difference by... September 6, 2021 ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 How I Took Charge of My Cancer Care and Found a... August 30, 2022 Load more HOT NEWS ESMO Calls for Cancer to Be at the Core of the... Hopes for the future of cancer research – a video from... Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera Vulnerability in Brain Tumors May Open Door to New Treatments
